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Abstract
Objective To develop a set of quality criteria for patient
decision support technologies (decision aids).
Design and setting Two stage web based Delphi process using
online rating process to enable international collaboration.
Participants Individuals from four stakeholder groups
(researchers, practitioners, patients, policy makers) representing
14 countries reviewed evidence summaries and rated the
importance of 80 criteria in 12 quality domains on a 1 to 9
scale. Second round participants received feedback from the
first round and repeated their assessment of the 80 criteria plus
three new ones.
Main outcome measure Aggregate ratings for each criterion
calculated using medians weighted to compensate for different
numbers in stakeholder groups; criteria rated between 7 and 9
were retained.
Results 212 nominated people were invited to participate. Of
those invited, 122 participated in the first round (77
researchers, 21 patients, 10 practitioners, 14 policy makers);
104/122 (85%) participated in the second round. 74 of 83
criteria were retained in the following domains: systematic
development process (9/9 criteria); providing information
about options (13/13); presenting probabilities (11/13);
clarifying and expressing values (3/3); using patient stories
(2/5); guiding/coaching (3/5); disclosing conflicts of interest
(5/5); providing internet access (6/6); balanced presentation of
options (3/3); using plain language (4/6); basing information
on up to date evidence (7/7); and establishing effectiveness
(8/8).
Conclusions Criteria were given the highest ratings where
evidence existed, and these were retained. Gaps in research
were highlighted. Developers, users, and purchasers of patient
decision aids now have a checklist for appraising quality. An
instrument for measuring quality of decision aids is being
developed.
Introduction
Clinical guidelines often recommend that healthcare profession-
als should involve patients in decisions about screening,
treatment, and other interventions,1–3 to help them to arrive at
informed choices. Patient decision aids are designed to support
patients in this process4; they are intended to supplement rather
than replace patient-practitioner interaction. They may be
leaflets, interactive media, or video or audio tapes. Patients may
use them to prepare for talking with a clinician, or a clinician may
provide them at the time of a visit to facilitate decision making.
At a minimum, patient decision aids provide information about
the options and their associated relevant outcomes. These tech-
nologies also help patients to personalise this information, to
understand that they can be involved in choosing among the
various options, to appreciate the scientific uncertainties
inherent in that choice, to clarify the personal value or desirabil-
ity of potential benefits relative to potential harms, to communi-
cate their values to their practitioners, and to gain skills in the
steps of collaborative decision making.1
Evidence describing the effectiveness and feasibility of
patient decision aids is substantial.5–8 Trials indicate that decision
aids are superior to standard counselling in improving patients’
knowledge and realistic expectations about the results of
treatments and other procedures. In most studies, outcomes such
as perceived involvement, agreement between values and choice,
and decisional conflict have changed in a desirable positive
direction.5 Decision aids can also affect the uptake of options,
reducing the use of some procedures (such as fewer
mastectomies in favour of breast conservation surgery9 or a
reduction in hysterectomy rates10), and increasing the use of oth-
ers (such as the uptake of colon cancer screening5). These effects
are desirable when decision aids are unbiased and the
motivation is to rectify variations in practice due to poor
comprehension or disregarding of patients’ preferences.
However, concerns will emerge if decision aids affect uptake
rates because of bias or inaccuracy.
By 1999, approximately 15 patient decision aids had been
developed in academic institutions. More than 500 now exist,
produced largely by a mix of not for profit and commercial
organisations. Many are easily available on the internet.11
However, their quality varies; some do not cite their evidence
sources, and others have presentational biases. Furthermore,
debate exists about underlying concepts12 and about the lack of
agreed quality criteria for these tools. Because patient decision
aids can have an important influence on choices made,13
developers need to have followed recognised methods, avoid
bias, and cite valid evidence sources.
An extra table, a statistical appendix, and a checklist are on bmj.com
Cite this article as: BMJ, doi:10.1136/bmj.38926.629329.AE (published 14 August 2006)
BMJ
BMJ Online First bmj.com page 1 of 6
Acting on this need, the International Patient Decision Aids
Standards (IPDAS) Collaboration was established at the 2nd
International Shared Decision Making conference (Swansea,
2003). The proposal to generate a quality framework was also
supported at the Society for Medical Decision Making (Chicago,
2003) and Society for Information Therapy (Utah, 2003). We
reviewed existing checklists for assessing the quality of
randomised trials (CONSORT),14 meta-analyses (QUOROM),15
practice guidelines (AGREE),16 and general patient
information.17–19 However, patient decision aids differ from scien-
tific studies and practice guidelines and aim to do more than
provide general information for patients. They are interventions
that recognise the need for both patients and professionals to
consider, at the individual level, the impact of uncertainties sur-
rounding many healthcare decisions; they communicate risk
probabilities and use methods to clarify values and guide
deliberation. Moreover, they use powerful and potentially
misleading strategies that have not been used in other quality
checklists. Aware of best practice regarding the development of
quality criteria,20 IPDAS adapted an approach used for
appraising clinical guidelines (AGREE collaboration)16 and
established an international collaboration of different stake-
holder groups. The aim was to achieve an international consen-
sus based framework of quality criteria for patient decision aids
that would act as a checklist for developers and users.
Methods
Substantive research evidence about the overall effectiveness of
patient decision aids exists,5 but little information is available
about which components and processes are most influential for
improving “decision quality.”13 IPDAS therefore decided that cri-
teria should be developed by using a recognised consensus
based approach,21 22 capable of integrating empirical evidence
where it exists and also the views of experts and a range of other
people, such as informed stakeholders, patients, health
professionals, policy makers, and potential purchasers of the
tools. We therefore established a Delphi consensus process.
Delphi consensus technique and study management
Considerable experience in using Delphi consensus techniques
exists,21 23 24 but few researchers have used the methods to
develop quality criteria among different stakeholder groups on
an international basis.25 26 To manage the task, we convened four
groups: a strategic steering group oversaw the project, an
evidence review group prepared background documents, a
methods group specified a two stage web based criteria rating
process (adapting the RAND appropriateness rating system27),
and a stakeholder selection group identified the people who
would be invited to serve as raters. The process comprised the
following steps.
Defining quality domains—Delegates at the 2003 conference
identified an initial list of quality areas from previous work5 and
expanded it into 12 broad quality domains (see extra table on
bmj.com). Members of the shared decision making electronic
listserve, composed of 181 interested academics and practition-
ers, discussed the validity of the 12 domains. Next, we used these
12 broad quality domains to specify which background evidence
reports were needed.
Developing background evidence reports—Twelve panels (a total
of 50 international experts) prepared “background evidence
reports” for each quality domain.28 Each report included defini-
tions of key concepts; theoretical links between the domain and
decision quality13; and evidence to support the inclusion or
exclusion of suggested domain criteria, including fundamental
studies28 and results from the systematic review of 34 randomised
trials.5 From these reports (available online28), we drafted quality
criteria.
Producing quality criteria—We subjected the quality criteria to
iterative consultation about comprehensiveness and subsequent
editing by the steering group, the methods group, the evidence
review groups panels,28 and finally by a plain language expert,
before a pilot rating exercise. We established a final set of 80
quality criteria.
Establishing participant stakeholder groups—We considered
four stakeholders groups to be relevant: patients, health
practitioners, policy makers, and decision aid developers and
researchers. The collaboration decided that the framework
would represent views among stakeholder groups equally, on the
basis of the view that decision aids should reflect a balance, if
possible, between positions taken by patients, researchers,
clinicians, and society at large over the attribution of priorities
and choices. We based statistical analyses (see below) on this
intent. Potential participants were nominated by the IPDAS Col-
laboration, by the Cochrane Collaboration Consumers Group,
and by word of mouth among the related networks. The
inclusion criteria were familiarity or awareness of patient
decision aids and an ability to provide ratings within a specified
time window. The researcher and developer group was
over-represented to allow wide participation, and we weighted
the group ratings to ensure equal contribution (see analysis).
Rating quality criteria—We invited nominated participants by
email to complete a two stage rating process, gave them access to
a password protected website,28 and asked them to complete a
short demographic questionnaire. For each quality domain, we
asked participants to read a short summary of the background
reports (full text was available by URL) and then rate the impor-
tance of quality criteria on a scale from 1 = not important to
9 = very important. Raters could also choose to add free text
comments (fig 1).We sent two email reminders in each round. At
the second round, we presented raters with a summary of the
results for each domain and the first round ratings for each of
the criteria (fig 1).
Analysis of ratings
After the first round, we calculated aggregate ratings and
summarised comments. To ensure equal weighting for each
stakeholder group in the overall rating, we obtained a weighted
median by calculating a separate empirical cumulative
distribution function for each group. We estimated the empirical
cumulative distribution function for a population with equal
numbers in each stakeholder group by taking an equally
weighted sum of these functions. We calculated the median of
this distribution (equimedian) by finding the value for which this
function equals 0.5. For further details on calculation of an equi-
median, see statistical appendix on bmj.com. We based
thresholds for retaining quality criteria in the framework on the
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Fig 1 Example of a criterion (second round). Quality domain=presenting
probabilities
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overall equimedian and the level of disagreement among partici-
pants at the second round. We considered that participants
“disagreed” if 30% or more of the ratings were in the lower third
(ratings 1-3) and 30% or more of the ratings were in the upper
third (ratings 7-9). We regarded quality criteria with an overall
equimedian rating of 7 to 9 (without disagreement) as
“important” and included them. We considered criteria rated as
4 to 6 (without disagreement) to be “equivocal.” We regarded cri-
teria rated with an equimedian of 1 to 3 as “not important.” We
also considered criteria that exhibited disagreement to be not
important. We based these thresholds on values used in other
settings.21 We used non-parametric analyses of variances to
calculate the potential impact of differences between stakeholder
groups’ ratings.29 We did sensitivity analyses to establish whether
the exclusion of stakeholder groups had an effect on the overall
results.
Results
Although listserve participants debated whether the domain
labelled “patient stories” should be included, we retained all 12
quality domains suggested for criterion development. Listserve
participants made no additions. We included the following qual-
ity domains in the final quality criterion framework: (1)
systematic development process; (2) providing information
about options; (3) presenting probabilities; (4) clarifying and
expressing values; (5) using patient stories; (6) guiding or coach-
ing in deliberation and communication; (7) disclosing conflicts of
interest; (8) delivering patient decision aids on the internet; (9)
balancing the presentation of options; (10) using plain language;
(11) basing information on up to date scientific evidence; and
(12) establishing effectiveness.
The table describes the participants in the first and second
rounds. We invited 212 people to the Delphi process (125
researchers/researcher practitioners, 44 patients, 25 policy mak-
ers, and 18 health professionals). Of those invited, 122 provided
ratings at the first round; 104/122 (85%) participants completed
both rating rounds. Participants were from 14 countries,
although most were from the United States (65), Canada (50), the
United Kingdom (44), and Australia (18).
The free text comments prompted the addition of three new
criteria for the second round (1.8b, 8.6, and 11.5b). The extra
table on bmj.com reports the equimedian ratings achieved for
each criterion after the second round. Of the 83 criteria, 41 were
given an overall equimedian rating of 9, 28 a rating of 8, and 7 a
rating of 7. Eight criteria (3.11, 3.12, 5.1, 5.3, 5.4, 6.4, 6.5, and 10.2)
had equivocal ratings (rated 4 to 6 without disagreement). Of the
13 criteria in the domain “presenting probabilities,” two had
equimedian ratings of 5 and 6 (3.11 “describe how probabilities
were calculated” and 3.12 “describe how probabilities were
derived for patient subgroups”). Three of the five criteria in the
domain “patient stories” (5.1, 5.3, and 5.4) all had equimedian
ratings of 6. Two of two criteria that focused on offering a
“trained coach to prepare patients to discuss decisions with their
Participants’ characteristics and responses by stakeholder group and country
No of participants invited
Round 1 Round 2
No Response rate (%) No Response rate (%)
Stakeholders
Patients 44 21 48 19 91
Practitioners 18 10 56 9 90
Policy makers 25 14 56 9 64
Researchers 125 77 62 67 87
Total 212 122 58 104 85
Country
Australia 18 12 67 11 92
UK 44 18 41 16 89
USA 65 45 69 40 89
Canada 50 30 60 24 80
China 1 0 0 0 0
Finland 2 0 0 0 0
France 7 5 71 4 80
Germany 2 1 50 1 100
Israel 1 1 0 1 100
Italy 1 1 0 1 100
Kenya 1 0 0 0 0
Netherlands 8 4 50 2 50
New Zealand 1 1 100 1 100
Norway 5 1 20 1 100
Spain 1 1 100 1 100
Switzerland 3 1 33 1 100
Uruguay 2 1 50 0 0
Total 212 122 58 104 85
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Fig 2 Criteria for which stakeholder effects were present at second round (see
table for data and P values)
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practitioners” had equimedian ratings of 5 (6.4 and 6.5). None of
the criteria had evidence of disagreement, although two criteria
(10.1 and 10.2 in the “plain language” domain) came close to this
threshold.
For 16 criteria, evidence existed of significant differences
between stakeholder groups’ ratings (table, fig 2). Compared with
other stakeholder groups, researchers generally gave lower
ratings to criteria. Although these group differences achieved
statistical significance, only five criteria had medians that
straddled the threshold for inclusion. Exclusion of any one set of
stakeholder results did not change the overall inclusion or exclu-
sion of criteria.
Discussion
Principal findings
This Delphi process, supported by summarised evidence reports,
has provided substantial consensus about a framework of quality
criteria for patient decision aids. The decision aid criteria that
were most strongly endorsed also had the greatest empirical
support. In addition, the process revealed areas of disagreement
and opportunities for further research. Where stakeholder
groups’ ratings differed, the researcher group tended to give
lower ratings, presumably because these participants were more
conservative about the feasibility of simultaneously achieving a
large number of quality criteria and perhaps more aware of the
difficulty in obtaining supportive empirical evidence. For exam-
ple, the use of “patient stories” in decision aids caused consider-
able discussion. Some researchers believe that patient decision
aids should avoid using patient stories until their impact is better
understood. Concerns exist because patient stories have the
potential to introduce significant bias and depend on how the
stories are selected and presented.30 Given that decision making
is strongly influenced by self identification with “similar others,”
this area needs further investigation. The values clarification
technique of describing the physical, emotional, and social effects
of options to help patients to explore “experienced utility” was
strongly endorsed.31 Another area of disagreement was about the
use of trained coaches to prepare patients to discuss options;
although the addition of coaching has shown positive effects,10
worries exist about its feasibility, and further empirical work
would be of value.
The endorsed criteria are available as a checklist (see
bmj.com). In this checklist, the first subset of criteria (content)
refer to the information, probabilities, values clarification, and
guidance in deliberation that are context specific—that is, specific
to the health condition and therapeutic/screening options
covered by a particular patient decision aid. The second subset of
criteria (development process) are generic, in that they refer to
design and developmental criteria that are relevant to all patient
decision aids, regardless of the health context. The third subset of
criteria (effectiveness) are also generic, in that they refer to the
general principles of fostering a high quality decision process
and a high quality choice. This checklist enables the users of
existing decision aids, such as patients and health professionals,
to assess the content, development process, and effectiveness of
patient decision aids they encounter. The framework for the
quality criteria that appear in the checklist, in conjunction with
the IPDAS Collaboration’s supporting background evidence
documents,28 form an important resource for the developers of
new decision aids who need empirical evidence about the differ-
ent components and processes required to produce a high qual-
ity decision aid. In this sense, the checklist is comparable to the
GRADE working group outputs.32
Furthermore, the quality criteria that appear in the checklist
could guide researchers in the decision sciences to create a vali-
dated quality assessment scale that could generate quantitative
scores. These quantitative data could, in turn, be used in
comparative studies of patient decision aids and in systematic
reviews of these technologies.5 In this sense, the checklist is com-
parable to the AGREE tool, which is used for the assessment of
clinical guidelines.16
Weaknesses and strengths
A potential weakness of the study is the extent to which the par-
ticipants were not independent of the research agenda. Although
summaries of empirical evidence were presented, some raters
might have considered patient decision aids to offer more
advantages than disadvantages and could have introduced bias.
We note, however, that consistency was high across groups and
that, where differences appeared, researchers generally gave
lower ratings than the other stakeholders. A second possible
weakness is that we asked the participants to rate the criteria
against only the “importance” of the criterion for the quality of a
decision aid. Ideally, factors such as measurability and feasibility
would have been included.27 However, we opted for high
response rates and attempted not to overburden participants.
A strength of the study is the appropriate use of a Delphi
consensus process.21 The method generated a wide “ownership”
of the exercise and involvement of many recognised research
groups in this field. Moreover, we took care to ensure the
availability of existing empirical evidence,28 the use of plain lan-
guage, and that equal weighting was given to stakeholder groups’
ratings.
Results in context
This study represents the first international effort to build on the
work of the Cochrane Collaboration’s systematic review group
and establish a normative consensus on quality criteria for
patient decision aids.5 We recognise that the checklist contains a
substantial number of criteria and might be considered to repre-
sent an “ideal” construction that may be difficult to attain. How-
ever, this quality framework emphasises the need to strive for
designs that have favourable effects on decision quality. The cri-
teria are not meant to be prescriptive; many different ways of
achieving the same ends exist, and an unresolved debate remains
about what constitutes a minimum set of domains and criteria
that should be met by a patient decision aid. Nevertheless, we
believe that the IPDAS Collaboration has set an agenda for both
developers and researchers. The development of future decision
aids should also be based on theoretical underpinning12 and on
the measurement of appropriate outcomes, in order to
determine whether patient decision aids accomplish their
primary objective—to improve the quality of decisions (the
extent to which patients’ decisions are consistent with their
informed values).13
Implications
Quality criteria for patient decision aids are relevant to patients,
healthcare professionals, healthcare service purchasers, and
policy makers, all of whom need to be confident about the devel-
opment and testing that these tools have undergone before their
release. The IPDAS Collaboration checklist is designed for exist-
ing users and for developers of new decision aids. To take the
field forward, two things are now needed: firstly, to use the IPDAS
framework as a basis for developing a validated instrument for
assessing what could be termed the internal quality (content and
technology) of the decision tool; secondly, to develop an agreed
way to measure with more precision the impact of such tools
Research
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(their efficacy and effectiveness) on a range of outcomes. At that
point that we may be able to examine in more depth the goal of
helping patients and their advisers to make the best healthcare
decisions.
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